169 related articles for article (PubMed ID: 38033123)
1. Serotonin 2A Receptor (5-HT
Duan W; Cao D; Wang S; Cheng J
Chem Rev; 2024 Jan; 124(1):124-163. PubMed ID: 38033123
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
Sekssaoui M; Bockaert J; Marin P; Bécamel C
Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441
[TBL] [Abstract][Full Text] [Related]
3. Structure-based discovery of nonhallucinogenic psychedelic analogs.
Cao D; Yu J; Wang H; Luo Z; Liu X; He L; Qi J; Fan L; Tang L; Chen Z; Li J; Cheng J; Wang S
Science; 2022 Jan; 375(6579):403-411. PubMed ID: 35084960
[TBL] [Abstract][Full Text] [Related]
4. Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT
de la Fuente Revenga M; Jaster AM; McGinn J; Silva G; Saha S; González-Maeso J
ACS Chem Neurosci; 2022 Aug; 13(16):2436-2448. PubMed ID: 35900876
[TBL] [Abstract][Full Text] [Related]
5. Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice.
Qu Y; Chang L; Ma L; Wan X; Hashimoto K
Pharmacol Biochem Behav; 2023 Jan; 222():173500. PubMed ID: 36476377
[TBL] [Abstract][Full Text] [Related]
6. "Selective" serotonin 5-HT
Casey AB; Cui M; Booth RG; Canal CE
Biochem Pharmacol; 2022 Jun; 200():115028. PubMed ID: 35381208
[TBL] [Abstract][Full Text] [Related]
7. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
8. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT
Pottie E; Dedecker P; Stove CP
Biochem Pharmacol; 2020 Dec; 182():114251. PubMed ID: 32998000
[TBL] [Abstract][Full Text] [Related]
9. Setup of a Serotonin 2A Receptor (5-HT2AR) Bioassay: Demonstration of Its Applicability To Functionally Characterize Hallucinogenic New Psychoactive Substances and an Explanation Why 5-HT2AR Bioassays Are Not Suited for Universal Activity-Based Screening of Biofluids for New Psychoactive Substances.
Pottie E; Cannaert A; Van Uytfanghe K; Stove CP
Anal Chem; 2019 Dec; 91(24):15444-15452. PubMed ID: 31725281
[TBL] [Abstract][Full Text] [Related]
10. 5-HT
Schmitz GP; Jain MK; Slocum ST; Roth BL
ACS Chem Neurosci; 2022 Aug; 13(16):2386-2398. PubMed ID: 35894503
[TBL] [Abstract][Full Text] [Related]
11. Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice.
de la Fuente Revenga M; Shah UH; Nassehi N; Jaster AM; Hemanth P; Sierra S; Dukat M; González-Maeso J
ACS Chem Neurosci; 2021 Mar; 12(5):831-844. PubMed ID: 33400504
[TBL] [Abstract][Full Text] [Related]
12. Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists.
Karaki S; Becamel C; Murat S; Mannoury la Cour C; Millan MJ; Prézeau L; Bockaert J; Marin P; Vandermoere F
Mol Cell Proteomics; 2014 May; 13(5):1273-85. PubMed ID: 24637012
[TBL] [Abstract][Full Text] [Related]
13. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors.
Vargas MV; Dunlap LE; Dong C; Carter SJ; Tombari RJ; Jami SA; Cameron LP; Patel SD; Hennessey JJ; Saeger HN; McCorvy JD; Gray JA; Tian L; Olson DE
Science; 2023 Feb; 379(6633):700-706. PubMed ID: 36795823
[TBL] [Abstract][Full Text] [Related]
14. Effects of the 5-HT
Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
[TBL] [Abstract][Full Text] [Related]
15. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Madsen MK; Fisher PM; Burmester D; Dyssegaard A; Stenbæk DS; Kristiansen S; Johansen SS; Lehel S; Linnet K; Svarer C; Erritzoe D; Ozenne B; Knudsen GM
Neuropsychopharmacology; 2019 Jun; 44(7):1328-1334. PubMed ID: 30685771
[TBL] [Abstract][Full Text] [Related]
16. The selective 5-HT
Jensen AA; Halberstadt AL; Märcher-Rørsted E; Odland AU; Chatha M; Speth N; Liebscher G; Hansen M; Bräuner-Osborne H; Palner M; Andreasen JT; Kristensen JL
Biochem Pharmacol; 2020 Jul; 177():113979. PubMed ID: 32298690
[TBL] [Abstract][Full Text] [Related]
17. 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.
Cameron LP; Patel SD; Vargas MV; Barragan EV; Saeger HN; Warren HT; Chow WL; Gray JA; Olson DE
ACS Chem Neurosci; 2023 Feb; 14(3):351-358. PubMed ID: 36630260
[TBL] [Abstract][Full Text] [Related]
18. Beyond the 5-HT
Cameron LP; Benetatos J; Lewis V; Bonniwell EM; Jaster AM; Moliner R; Castrén E; McCorvy JD; Palner M; Aguilar-Valles A
J Neurosci; 2023 Nov; 43(45):7472-7482. PubMed ID: 37940583
[TBL] [Abstract][Full Text] [Related]
19. Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
Poulie CBM; Pottie E; Simon IA; Harpsøe K; D'Andrea L; Komarov IV; Gloriam DE; Jensen AA; Stove CP; Kristensen JL
J Med Chem; 2022 Sep; 65(18):12031-12043. PubMed ID: 36099411
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic effects of arketamine, but not hallucinogenic psychedelic DOI nor non-hallucinogenic psychedelic analog lisuride, in lipopolysaccharide-treated mice and mice exposed to chronic restrain stress.
Liu G; Ma L; Qu Y; Wan X; Xu D; Zhao M; Murayama R; Hashimoto K
Pharmacol Biochem Behav; 2023 Dec; 233():173659. PubMed ID: 37844631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
